Eli Lilly and Company (NYSE:LLY) is one of the Jim Cramer Reveals Potential US Rare Earth Trump Card & Discusses These 11 ...

Hims & Hers lost a valuable collaboration with Novo Nordisk over compounded GLP-1s. Could it hurt the company's potential to ...

Eli Lilly & Co. is bouncing back after a turbulent period, riding out volatility and posting a strong revenue increase in Q1 ...

Eli Lilly (NYSE: LLY) has been on fire over the past two years. The drugmaker has generated excellent financial results and ...

In its first-quarter 2025 investor letter, Macquarie Large Cap Growth Fund highlighted stocks such as Eli Lilly and Company ...

Despite Nektar’s share price shooting up as much as 175% on Tuesday, William Blair maintained that “there is an absence of ...

The FDA label update boosts GE HealthCare’s Vizamyl to a market advantage despite the emergence of blood-based tests.

Compounded weight loss drugs have been mostly off the market for about a month, but the weight loss drug industry remains as unsettled as ever.

Eli Lilly has had a presence in Kinsale since 1978, a relationship that has seen both places prosper and grow across the ...

China-based MindRank’s oral glucagon-like peptide-1 receptor agonist (GLP-1RA) has achieved up to 10.5% weight loss in a ...

With patents expiring and the obesity market opening up, major players in the weight-loss market are lining up to see what will follow the likes of Wegovy and Zepbound. With Morgan Stanley estimating ...

Eli Lilly and Company (NYSE:LLY) is one of the best Fortune 500 stocks to buy according to billionaires. On June 20, Eli Lilly reported a positive reception for its blockbuster drug Mounjaro in India ...